OMNICEF Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Omnicef, and when can generic versions of Omnicef launch?

Omnicef is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in OMNICEF is cefdinir. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the cefdinir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Omnicef

A generic version of OMNICEF was approved as cefdinir by LUPIN on May 19^th, 2006.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for OMNICEF?
What are the global sales for OMNICEF?
What is Average Wholesale Price for OMNICEF?

Summary for OMNICEF

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	14
Patent Applications:	4,966
DailyMed Link:	OMNICEF at DailyMed

Drug patent expirations by year for OMNICEF

Recent Clinical Trials for OMNICEF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Thomas Jefferson University	Phase 4
The Cleveland Clinic	Phase 4
St. Joseph's Hospital and Medical Center, Phoenix	Phase 4

See all OMNICEF clinical trials

US Patents and Regulatory Information for OMNICEF

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	OMNICEF	cefdinir	CAPSULE;ORAL	050739-001	Dec 4, 1997		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	OMNICEF	cefdinir	FOR SUSPENSION;ORAL	050749-001	Dec 4, 1997		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	OMNICEF	cefdinir	FOR SUSPENSION;ORAL	050749-002	Jul 29, 2004		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for OMNICEF

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	OMNICEF	cefdinir	CAPSULE;ORAL	050739-001	Dec 4, 1997	⤷ Sign Up	⤷ Sign Up
Abbvie	OMNICEF	cefdinir	FOR SUSPENSION;ORAL	050749-002	Jul 29, 2004	⤷ Sign Up	⤷ Sign Up
Abbvie	OMNICEF	cefdinir	FOR SUSPENSION;ORAL	050749-001	Dec 4, 1997	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for OMNICEF

See the table below for patents covering OMNICEF around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Ireland	67348	Novel crystalline 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer)	⤷ Sign Up
South Africa	8805709		⤷ Sign Up
Germany	3853901		⤷ Sign Up
Mexico	9203468	NOVEDOSO ACIDO 7-[2-(2-AMINOTIAZOL-4-IL)-2-HIDROXIIMINOACETAMIDO]-3-VINIL-3-CEFEM-4-C ARBOXILICO (ISOMERO SIN) CRISTALINO.	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for OMNICEF

Recent Clinical Trials for OMNICEF

Make Better Decisions: Try a trial or see plans & pricing